Lifecore Biomedical Lands Key Commercial Manufacturing Pact for Aesthetic Product
LFCR is trading near its 52-week low of $3.9 (4.4% above the low) on elevated volume (3.6× avg).
Summary
Lifecore Biomedical has signed a commercial site transfer agreement with a leading medical aesthetics company for the manufacturing of an established, approved product. This marks the third such commercial site transfer agreement for Lifecore in five months, demonstrating successful execution of its strategic plan. The agreement is significant as it is expected to generate commercial revenue within 24 months and contribute to the company's targeted 2029 revenue CAGR of 12%. This positive development provides a potential offset to the recent news of the company expecting to lose a customer and issuing lower revenue guidance, offering a more optimistic outlook for future revenue streams. Traders will be watching for updates on the technical transfer process and the commencement of commercial revenue generation.
At the time of this announcement, LFCR was trading at $4.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $150.7M. The 52-week trading range was $3.90 to $8.98. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.